Compare ARBK & SYBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ARBK | SYBX |
|---|---|---|
| Founded | 2017 | N/A |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.6M | 15.2M |
| IPO Year | 2021 | N/A |
| Metric | ARBK | SYBX |
|---|---|---|
| Price | $5.20 | $1.11 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 96.7K | 68.3K |
| Earning Date | 05-01-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $24,043,000.00 | N/A |
| Revenue This Year | $183.90 | N/A |
| Revenue Next Year | $26.78 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.24 | $0.90 |
| 52 Week High | $205.20 | $1.96 |
| Indicator | ARBK | SYBX |
|---|---|---|
| Relative Strength Index (RSI) | 76.73 | 25.48 |
| Support Level | $0.12 | $1.01 |
| Resistance Level | $28.64 | $1.20 |
| Average True Range (ATR) | 1.74 | 0.09 |
| MACD | 0.56 | -0.03 |
| Stochastic Oscillator | 17.51 | 9.72 |
Argo Blockchain PLC is a blockchain technology company focused on the large-scale mining of Bitcoin. It mines bitcoin using purpose-built computers (or mining machines) to solve complex cryptographic algorithms on the blockchain in exchange for rewards and fees denominated in the native token of that blockchain network. The company acquires and deploys mining technology solutions in North American facilities that utilize predominantly renewable and inexpensive electricity.
Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a lead program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. These drug candidates target specific biological pathways, leveraging Escherichia coli Nissle 1917 for consistency and safety. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one segment-discovery and development of Synthetic Biotics-pioneering transformative treatments for serious diseases.